Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

Nature Medicine volume 4, pages 328–332 (1998)Cite this article

Abstract

Melanoma is the main cause of death in patients with skin cancer1. Cytotoxic T lymphocytes (CTLs) attack melanoma cells in an HLA-restricted and tumor antigen-specific manner. Several melanoma-associated tumor antigens have been identified2. These antigens are suitable candidates for a vaccination therapy of melanoma. Dendritic cells (DCs) are antigen-presenting cells (APCs) specialized for the induction of a primary T-cell response3. Mouse studies have demonstrated the potent capacity of DCs to induce antitu-mor immunity4–11. In the present clinical pilot study, DCs were generated in the presence of granulocyte/macrophage-colony stimulating factor (GM-CSF) and interleukin 4 (IL-4) and were pulsed with tumor lysate or a cocktail of peptides known to be recognized by CTLs, depending on the patient's HLA haplotype. Keyhole limpet hemocyanin (KLH) was added as a CD4 helper antigen and immunological tracer molecule. Sixteen patients with advanced melanoma were immunized on an outpatient basis. Vaccination was well tolerated. No physical sign of autoimmunity was detected in any of the patients. DC vaccination induced de-layed-type hypersensitivity (DTH) reactivity toward KLH in all patients, as well as a positive DTH reaction to peptide-pulsed DCs in 11 patients. Recruitment of peptide-specific CTLs to the DTH challenge site was also demonstrated. Therefore, antigen-specific immunity was induced during DC vaccination. Objective responses were evident in 5 out of 16 evaluated patients (two complete responses, three partial responses) with regression of metastases in various organs (skin, soft tissue, lung, pancreas) and one additional minor response. These data indicate that vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma. Further studies are necessary to demonstrate clinical effectiveness and impact on the survival of melanoma patients.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. MacKie, R.M. Melanoma prevention and early detection. Br. Med. Bull. 51 570–583 (1995).

    Article  CAS  PubMed  Google Scholar 

  2. Rosenberg, S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18, 175–182 (1997).

    Article  CAS  PubMed  Google Scholar 

  3. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271–296(1991).

    Article  CAS  PubMed  Google Scholar 

  4. Flamand, V. et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24, 605–610 (1994).

    Article  CAS  PubMed  Google Scholar 

  5. Mayordomo, J.I. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med. 1, 1297–1302(1995).

    Article  CAS  PubMed  Google Scholar 

  6. Mayordomo, J.I. et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183, 1357–1365 (1996).

    Article  CAS  PubMed  Google Scholar 

  7. Paglia, P. et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317–322 (1996).

    Article  CAS  PubMed  Google Scholar 

  8. Porgador, A. et al. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918–2926 (1996).

    CAS  PubMed  Google Scholar 

  9. Shimizu, J. et al. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. J. Immunol. 142, 1053–1059 (1989).

    CAS  PubMed  Google Scholar 

  10. Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1 -associated cytokines. Exp. Med. 183, 87–97 (1996).

    Article  CAS  Google Scholar 

  11. Celluzzi, C. et al. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283–287 (1996).

    Article  CAS  PubMed  Google Scholar 

  12. Marchand, M. et al. Tumor regression responses in melanoma patients with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883–885 (1995).

    Article  CAS  PubMed  Google Scholar 

  13. Jäger, E. et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66, 162–169 (1996).

    Article  Google Scholar 

  14. Cormier, J.N. et al. Enhancement of cellular immunity in melanoma patient immunized with a peptide from MART-1/Melan-A. Cancer J. Sci. Am. 3, 37–44 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Grabbe, S. et al. Dendritic cells as initiators of tumor immune responses—a possible strategy for tumor immunotherapy? Immunol. Today 16, 117–121 (1995).

    Article  CAS  PubMed  Google Scholar 

  16. Lanzavecchia, A. Identifying strategies for immune intervention. Science 260, 937–944 (1993).

    Article  CAS  PubMed  Google Scholar 

  17. Peters, J.H. et al. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol. Today 17, 273–278 (1996).

    Article  CAS  PubMed  Google Scholar 

  18. Caux, C. er al. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360, 258–261 (1992).

    Article  CAS  PubMed  Google Scholar 

  19. Romani, N. et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83–93 (1994).

    Article  CAS  PubMed  Google Scholar 

  20. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-alpha. J. Exp. Med 179, 1109–111 (1994).

    Article  CAS  PubMed  Google Scholar 

  21. Bennett, S.R.M. et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ help. J. Exp. Med. 186, 65–70 (1997).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zinkernagel, R.M. et al. On immunological memory. Annu. Rev. Immunol. 14, 333–367. (1996).

    Article  CAS  PubMed  Google Scholar 

  23. Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52–58 (1996).

    Article  CAS  PubMed  Google Scholar 

  24. Mukherji, B. et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad Sci. USA 92, 8078–802 (1995).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Alijagic, S. et al. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur. J. Immunol. 25, 3100–3107 (1995).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Zurich Medical School, Gloriastrasse 31, 8091, Zurich, Switzerland

    Frank O. Nestle, Michel Gilliet, Reinhard Dummer & Günter Burg

  2. Clinical Cooperation Unit for Dermatooncology (DKFZ) at the Klinikum Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1, 68135, Mannheim, Germany

    Selma Alijagic, Yuansheng Sun & Dirk Schadendorf

  3. Department of Dermatology, University of Münstervon, Esmarck Str. 56, 48149, Münster, Germany

    Stephan Grabbe

Authors
  1. Frank O. Nestle
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Selma Alijagic
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Michel Gilliet
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Yuansheng Sun
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Stephan Grabbe
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Reinhard Dummer
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Günter Burg
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Dirk Schadendorf
    View author publications

    You can also search for this author inPubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nestle, F., Alijagic, S., Gilliet, M. et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells. Nat Med 4, 328–332 (1998). https://doi.org/10.1038/nm0398-328

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0398-328

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing